Can-Fite BioPharma Ltd. (TASE: CFBI), (OTCQB: CANFY), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it executed confidentiality agreements with 10 established pharmaceutical and biotechnology companies with respect to potential negotiations for the commercialization of CF101 for the treatment of autoimmune inflammatory indications. As previously indicated, Can-Fite expects to release the clinical data from its Phase IIb CF101 study in Rheumatoid Arthritis during the last two weeks of 2013.
"We look forward to the data release from the Phase IIb advanced clinical study of CF101 for the treatment of Rheumatoid Arthritis. The company is also excited about the interest expressed by the pharmaceutical and biotechnology companies with which it recently executed confidentiality agreements," stated Can-Fite's Chief Executive Officer, Dr. Pnina Fishman.
CF101 is the most advanced drug candidate in Can-Fite's pipeline and is currently being developed for the treatment of autoimmune inflammatory indications including Rheumatoid Arthritis (Phase IIb) and Psoriasis (Phase II/III). According to GlobalData, the global Rheumatoid Arthritis market in 2010 was approximately $12 billion and is estimated to increase to $18 billion by 2020. The psoriasis market has been estimated by GlobalData at $3.3Billion in 2010 and is likewise estimated to increase to $6.7 billion by 2018.
As previously announced by Can-Fite on October 15, 2013, the CF101 drug, as developed by Can-Fite, was recently selected as one of the "Top Autoimmune/Anti-Inflammatory Disease Projects to Watch" by Elsevier Business Intelligence, the publisher of In Vivo and The Pink Sheet, and a global leader in the field of healthcare industry information. Many companies selected by Elsevier in previous years have gone on to establish major partnerships with large pharmaceutical companies.
New blood test shows promise in early detection of ovarian cancer